A carregar...
Phosphodiesterase Inhibitors for Alzheimer’s Disease: A Systematic Review of Clinical Trials and Epidemiology with a Mechanistic Rationale
BACKGROUND: Preclinical studies, clinical trials, and reviews suggest increasing 3’,5’-cyclic adenosine monophosphate (cAMP) and 3’,5’-cyclic guanosine monophosphate (cGMP) with phosphodiesterase inhibitors is disease-modifying in Alzheimer’s disease (AD). cAMP/protein kinase A (PKA) and cGMP/protei...
Na minha lista:
| Publicado no: | J Alzheimers Dis Rep |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
IOS Press
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7369141/ https://ncbi.nlm.nih.gov/pubmed/32715279 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3233/ADR-200191 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|